AVITA Medical/$RCEL
1D1W1MYTD1Y5YMAX
Capital at risk
About AVITA Medical
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
- Ticker
- $RCEL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 226
- Headquarters
- Valencia, United States
- Website
- avitamedical.com
AVITA Medical Metrics
BasicAdvanced
$322M
-
-$1.44
2.02
-
Price and volume
Market cap
$322M
Beta
2.02
52-week high
$11.39
52-week low
$3.22
Average daily volume
593K
Financial strength
Current ratio
0.413
Quick ratio
0.306
Long term debt to equity
-6.545
Total debt to equity
-174.154
Interest coverage (TTM)
-4.45%
Profitability
EBITDA (TTM)
-32.764
Gross margin (TTM)
81.56%
Net profit margin (TTM)
-56.96%
Operating margin (TTM)
-46.56%
Effective tax rate (TTM)
-0.05%
Revenue per employee (TTM)
$330,000
Management effectiveness
Return on assets (TTM)
-41.56%
Return on equity (TTM)
211.55%
Valuation
Price to revenue (TTM)
4.127
Price to book
-11.57
Price to tangible book (TTM)
-9.73
Price to free cash flow (TTM)
-12.318
Free cash flow yield (TTM)
-8.12%
Free cash flow per share (TTM)
-0.845
Growth
Revenue change (TTM)
1.00%
Earnings per share change (TTM)
-26.91%
3-year revenue growth (CAGR)
22.79%
3-year earnings per share growth (CAGR)
5.74%
What the Analysts think about AVITA Medical
Analyst ratings (Buy, Hold, Sell) for AVITA Medical stock.
Analyst projections of the future price of AVITA Medical stock.
Bulls say / Bears say
Analysis of U.S. national burn registry data shows the RECELL System reduces hospital length of stay by an average of 36% versus traditional skin grafting, underscoring its strong clinical efficacy and potential cost savings. (Reuters)
Q2 2026 net revenue was $21.7 million, up 18% year-over-year and 13% sequentially, driven by expanding adoption of RECELL in key burn centers. (SEC)
Management raised full-year 2026 revenue guidance to $86 million–$89 million (20%–24% growth), up from $80 million–$85 million, reflecting confidence in sustained commercial momentum. (SEC)
AVITA Medical reported a net loss of $10.6 million (loss of $0.35 per share) in Q1 2026, underscoring ongoing profitability challenges. (SEC)
Net cash use for Q2 2026 improved to $3.2 million from $9.9 million in Q1, but remained significant against a quarter-end cash balance of $11.1 million, indicating a constrained cash runway. (SEC)
International sales of $0.9 million in Q2 2026 represented under 5% of total net revenue, highlighting limited global market penetration despite multiple regulatory approvals. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 20 Aug 2026.
AVITA Medical Financial Performance
Revenues and expenses
AVITA Medical Earnings Performance
Company profitability
Upcoming events
No upcoming events
AVITA Medical News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.